PT - JOURNAL ARTICLE AU - Mongkolsucharitkul, Pichanun AU - Surawit, Apinya AU - Sookrung, Nitat AU - Tungtrongchitr, Anchalee AU - Phisalprapa, Pochamana AU - Sayabovorn, Naruemit AU - Srivanichakorn, Weerachai AU - Washirasaksiri, Chaiwat AU - Auesomwang, Chonticha AU - Sitasuwan, Tullaya AU - Chaisathaphol, Thanet AU - Tinmanee, Rungsima AU - Chayakulkeeree, Methee AU - Phoompoung, Pakpoom AU - Tangjittipokin, Watip AU - Senawong, Sansanee AU - Sanpawitayakul, Gornmigar AU - Muangman, Saipin AU - Mayurasakorn, Korapat AU - the SPHERE Investigators TI - Immunity response against mild-to-moderate breakthrough COVID-19 AID - 10.1101/2022.05.30.22275050 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.30.22275050 4099 - http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275050.short 4100 - http://medrxiv.org/content/early/2022/05/31/2022.05.30.22275050.full AB - BACKGROUND The Omicron variant prevails the Delta variant after December 2021 in Thailand. Both variants of concern embody diverse epidemiological trends and immunogenicity, raising enormous public health concerns. We determined whether biological and clinical characteristics and immunogenicity of patients differ between Delta and Omicron during post-coronavirus disease 2019 (COVID-19) stage.METHODS A retrospective cohort study involved patients with mild-to-moderate COVID-19 who were under a home isolation (HI) strategy. Clinical outcomes and laboratory data of 2704 and 2477 patients during the Delta and Omicron pandemics were analyzed, respectively. We evaluated anti-receptor binding domain immunoglobulin G (anti-RBD IgG) and surrogate viral neutralizing (sVNT) activity in a subset of 495 individuals post-COVID-19 infection during the Delta pandemic.RESULTS Eighty-four percent of all patients received antiviral treatment. The peak cycle threshold (Ct) values, which inversely related to viral load, were lower in the Omicron (19 [IQR=17-22]) compared with the Delta (21 [IQR=18-26]; p<0.001), regardless of vaccination status. Upper respiratory tract symptoms were common signs during the Omicron compared with the Delta pandemic. At least two-dose vaccination reduced the chance of hospital readmissions by 10–30% and death by less than 1%. Furthermore, anti-RBD IgG and sVNT against the Delta variants tended to be higher among the older individuals after post-COVID 19 infections and expressed in the long interval after two-dose vaccination than in other groups.CONCLUSIONS Mild-to-moderate Delta and Omicron breakthrough infection with prior full vaccination is limitedly immunogenic; thereby exerting reduced protection against reinfection and infection from novel variants. However, this may be only sufficient to prevent hospitalization and death, particularly in countries where vaccines are limited. (ClinicalTrials.gov number, NCT05328479.)Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Faculty of Medicine Siriraj Hospital, Mahidol University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board, Faculty of Medicine Siriraj Hospital, Mahidol University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.